HIGHLIGHTS
- What: The authors aimed to evaluate the safety and efficacy of monthly high-dose vitamin D 3 supplementation and its implications on bone mineral density (BMD) and HRQoL in patients with SCD and healthy controls.
- Who: Diana Hanna from the We enrolled , children with SCD (HbSS, HbSβ, thalassemia genotype), aged ≤ , years old, male or female at a steady state (≥ , month from blood transfusion and ≥ , days following one of the SCD complications as hospitalization for VOC or acute chest syndrome (ACS)), stable hemoglobin (Hb) level near their usual baseline, and stable dose of hydroxyurea (mg/kg . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.